Risk index for predicting complications and prognosis in Thai patients with neutropenia and fever

Journal of the Medical Association of Thailand

Volumn 86, Issue 3, 2003, Pages 212-223

  Chayakulkeeree, Methee ^a   Thamlikitkul, Visanu ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

Author keywords

Agranulocytosis; Febrile Neutropenia; Neutropenia; Prognosis

Indexed keywords

AMIKACIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; ANTINEOPLASTIC AGENT; CEFEPIME; CEFPIROME; CEFTAZIDIME; CEFTRIAXONE; CIPROFLOXACIN; CLINDAMYCIN; CLOXACILLIN; GENTAMICIN; IMIPENEM; MEROPENEM; METRONIDAZOLE; NETILMICIN;

ADOLESCENT; ADULT; AGED; ARTICLE; BACTEREMIA; CANCER CHEMOTHERAPY; CANCER CONTROL; DEHYDRATION; EPIDEMIOLOGICAL DATA; FEBRILE NEUTROPENIA; FEMALE; GRAM NEGATIVE BACTERIUM; HEMATOLOGIC MALIGNANCY; HUMAN; INFECTION; INFECTION RISK; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MORTALITY; MULTIVARIATE ANALYSIS; PREDICTION; PROGNOSIS; SCORING SYSTEM; SOLID TUMOR; THAILAND; TREATMENT OUTCOME; TREATMENT PLANNING; AGE DISTRIBUTION; COHORT ANALYSIS; COMPARATIVE STUDY; FEVER; GRAM NEGATIVE INFECTION; ISOLATION AND PURIFICATION; MIDDLE AGED; NEOPLASM; NEUTROPENIA; NONPARAMETRIC TEST; PREDICTION AND FORECASTING; PROBABILITY; REGISTER; RISK ASSESSMENT; RISK FACTOR; SEX RATIO; STATISTICAL MODEL; SURVIVAL;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COHORT STUDIES; FEMALE; FEVER; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; NEOPLASMS; NEUTROPENIA; PREDICTIVE VALUE OF TESTS; PROBABILITY; REGISTRIES; RISK ASSESSMENT; RISK FACTORS; SEX DISTRIBUTION; STATISTICS, NONPARAMETRIC; SURVIVAL ANALYSIS; THAILAND;

EID: 0037867841     PISSN: 01252208     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Bodey GP, Buckley M, Sathe YS, Freireich EJ. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 1996; 64: 328-40.
2. Schimpff S, Satterlee W, Young VM, Serpick A. Empiric therapy with carbenicillin and gentamicin for febrile patients with cancer and granulocytopenia. N Eng J Med 1971; 284: 1061-5.
3. Talcott JA, Finberg R, Mayer RJ, et al. The medical course of cancer patients with fever and neutropenia. Clinical identification of a low-risk subgroup at presentation. Arch Intern Med 1998; 148: 2561-8.
4. Pizzo PA, Hathorn JW, Hiemenz J, et al. A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia. N Eng J Med 1986; 315: 552-8.
5. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. Three antibiotic regimens in the treatment of infection in febrile granulocytopenic patients with cancer. J Infect Dis 1978; 137: 14-29.
6. Hughes WT, Armstrong D, Bodey GP. Guidelines from the infectious diseases society of America: 1997 guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Clin Infect Dis 1997; 25: 551-73.
7. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. Combination of amikacin and carbenicillin with or without cefazolin as empirical treatment of febrile neutropenic patients. J Clin Oncol 1983; 1: 597-603.
8. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. Ceftazidime combination with short or long course of amikacin for empirical therapy of gram-negative bacteremia in cancer patients with granulocytopenia. N Eng J Med 1987; 317: 1692-8.
9. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. Prospective randomized comparison of three antibiotic regimens for empirical therapy of suspected bacteremic infection in febrile granulocytopenic patients. Antimicrob Agents Chemother 1986; 29: 263-70.
10. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. Vancomycin added to empirical combination antibiotic therapy for fever in granulocytopenic cancer patients. J Infect Dis 1991; 163: 951-8.
11. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. Efficacy and toxicity of single daily doses of amikacin and ceftriaxone versus multiple daily doses of amikacin and ceftazidime for infection in patients with cancer and granulocytopenia. Ann Intern Med 1993; 119: 584-93.
12. Kanitsap N, Auewarakul C. Outcome of febrile neutropenia in patients with leukemia and lymphoma in Siriraj Hospital. Siriraj Hosp Gaz 1999; 51: 857-65.
13. Zinner SH. Changing epidemiology of infections in patients with neutropenia and cancer: Emphasis on gram-positive and resistant bacteria. Clin Infect Dis 1999; 29: 490-4.
14. Jones RN. Contemporary antimicrobial susceptibility patterns of bacterial pathogens commonly associated with febrile patients with neutropenia. Clin Infect Dis 1999; 29: 495-507.
15. Talcott JA, Siegel RD, Finberg R. et al. Risk assessment in cancer patients with fever and neutropenia: A prospective, two-center validation of a prediction rules. J Clin Oncol 1992; 10: 316-22.
16. Klastersky J, Paesmans M, Rubenstein EB. et al. The multinational association for supportive care in cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 2000; 18: 3038-51.
17. Rolston KVI. New trends in patient management: Risk-based therapy for febrile patients with neutropenia. Clin Infect Dis 1999; 29: 515-21.
18. Rolston KVI, Rubenstein EB. Freifeld A. Early empiric antibiotic therapy for febrile neutropenia patients at low risk. Infect Dis Clin North Am 1996; 10: 223-37.
19. Leong DCS, Kinlay S, Ackland S, et al. Low-risk febrile neutropenia in a medical oncology unit. Aust NZ J Med 1997; 27: 403-7.
20. Talcott JA, Whalen A, Clark J, Rieker PP, Finberg R. Home antibiotic therapy for low-risk cancer patients with fever and neutropenia: A pilot study of 30 patients based on a validated prediction rule. J Clin Oncol 1994; 12: 107-14.
21. Malik IA, Khan WA, Karim M, Aziz Z, Khan MA. Feasibility of outpatient management of fever in cancer patients with low-risk neutropenia: Results of a prospective randomized trial. Am J Med 1995; 98: 224-31.
22. Rubinstein EB, Rolston K, Benjamin RS, et al. Outpatient treatment of febrile episodes in low-risk neutropenic patients with cancer. Cancer 1993; 71: 3640-6.
23. Uzun O, Anaissie EJ. Outpatient therapy for febrile neutropenia: Who when and how? J Antimicrob Chemother 1999; 43: 317-20.
24. Hidalgo M, Hornedo J, Lumbreras C, et al. Outpatient therapy with oral ofloxacin for patients with low risk neutropenia and fever: A prospective randomized clinical trial. Cancer 1999; 85: 213-9.
25. Kern WV, Cometta A, de Bock R, Langenaeken J, Paesmans M, Gaya H. Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy. N Engl J Med 1999; 341: 312-8.
26. Freifeld A, Marchigiani D, Walsh T, et al. A double-blind comparison of empirical oral and intravenous antibiotic therapy for low risk febrile patients with neutropenia during cancer chemotherapy. N Eng J Med 1999; 341: 305-11.
27. Leelasupasri S. Febrile neutropenia. In: An update on infectious diseases V. Infectious Diseases Association of Thailand 1997: 230-45.
28. Feld R. Vancomycin as part of initial empirical antibiotic therapy for febrile neutropenia in patients with cancer: Pros and cons. Clin Infect Dis 1999; 29: 503-7.
29. Hughes WT, Armstrong D, Bodey GP, et al. Guidelines from the Infectious Diseases Society of America: 2002 guidelines for the use of antimicrobial agents in neutropenic patients with fever. Clin Infect Dis 2002; 34: 730-51.